Ubiquitin ligase KPC1 promotes processing of P105 NF-κB1 to p50, eliciting strong tumor suppression
The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.
1. A method of treating cancer in a subject comprising the step of administering to said subject a therapeutically effective amount of:
(b) an expression vector comprising a nucleic acid that encodes a fused protein comprising the KPC1 sequence as set forth in SEQ ID NO: 4,
wherein said method comprises administering the expression vector as described in (b).
2. The method of claim 1 , wherein said expression vector is comprised within a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
3. The method of claim 1 , wherein the cancer is breast cancer, bone osteosarcoma, or glioblastoma.
4. A method of treating cancer in a subject comprising the step of administering to said subject a therapeutically effective amount of:
(b) an expression vector comprising a nucleic acid that encodes a fused protein comprising the KPC1 sequence as set forth in SEQ ID NO: 4,
wherein said fused protein comprises an immunoglobulin, an antibody, an albumin, an albumin-binding moiety, or a combination thereof.
5. The method of claim 4 , wherein said immunoglobulin comprises IgG.
6. The method of claim 4 , wherein said expression vector is comprised within a pharmacuetical composition comprising a pharmaceutically acceptable carrier.
7. The method of claim 4 , wherein the cancer is breast cancer, bone osteosarcoma, or glioblastoma.